SNDX News and Press, Syndax Pharmaceuticals Inc.

2026-02-27 12:10:30 ET Image source: The Motley Fool. Feb. 26, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-26 22:48:23 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P....

2026-02-26 22:47:48 ET Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call February 26, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

2026-02-26 16:38:18 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Syndax Pharmaceuticals, Inc...

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-25 17:35:59 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Syndax Pharmaceuticals, Inc...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thurs...

2026-02-12 05:44:44 ET Thesis: Preliminary 2025 results indicate continued momentum Syndax Pharmaceuticals ( SNDX ) recently announced some preliminary FY25 financial results, and I have to say, they do show some decent commercial and operational progress. The main highlight...

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerg...